The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 4, p. 841, doi. 10.3390/cells9040841
- By:
- Publication type:
- Article
Works by Titze-de-Almeida, Simoneide S.
Results: 4
1
2
Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury.
- Published in:
- Neurotoxicity Research, 2019, v. 36, n. 1, p. 117, doi. 10.1007/s12640-019-00043-9
- By:
- Publication type:
- Article
3
Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
- Published in:
- Molecular Diagnosis & Therapy, 2020, v. 24, n. 1, p. 61, doi. 10.1007/s40291-019-00438-6
- By:
- Publication type:
- Article
4
Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
- Published in:
- Molecular Diagnosis & Therapy, 2020, v. 24, n. 1, p. 49, doi. 10.1007/s40291-019-00434-w
- By:
- Publication type:
- Article